메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Ping An Good Doctor (1833.HK) Reports Solid Interim Results with…

HONG KONG, Aug. 20, 2025 -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June 30, 2025, on August 19, 2025. Following its return to profitability in 2024, the Company maintained high growth and improved profitability during the reporting period, with core business development and continuous advancement in its medical AI capabilities. In terms of financial performance, the Company recorded revenue of RMB2.5 billion during the period, representing a year-on-year increase of
- 김갑성 기자
- 2025-08-20 19:19
First Patient Dosed in Pivotal Phase III Trial of Cadonilimab (PD-1…

HONG KONG, Aug. 20, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody developed by Akeso, in combination with chemotherapy for the perioperative treatment of resectable gastric/gastroesophageal junction (G/GEJ) adenocarcinoma. The COMPASSION-33 study represents the third Phase III trial for cadonilimab in gastric cancer. The study aims to improve the radical resectio
- 김갑성 기자
- 2025-08-20 16:11
DKSH Healthcare Establishes Industry Benchmark in Carbon…

DKSH Business Unit Healthcare has reached a significant milestone in building a more sustainable healthcare supply chain by successfully tracking carbon emissions across its value chain through a collaboration with UOB FinLab's GreenTech Accelerator and Smart Tradzt in Thailand. This achievement also marks the implementation of a reusable cold-chain packaging solution. The initiative underscores DKSH Healthcare's ongoing commitment to environmental responsibility and its proactive approach to advancing sustainable business practices. BANGKOK, Aug. 20, 2025 -- DKSH Business Unit
- 김갑성 기자
- 2025-08-20 12:00
Vital Materials Released Quantum Flux Photon Counting CT (P…

BEIJING, Aug. 20, 2025 -- From August 15-17, the 31st China International Medical Equipment Exhibition and Scientific Conference (China-Hospeq 2025) was held in Beijing. Vital Materials officially launched the VITA Genesis, China's fully proprietary Photon Counting CT (PCCT) scanner, marking the entry of global medical imaging technology into the "Quantum Flux" sensing era and empowering Chinese innovation in precision diagnostics and treatment. The Photon Counting Detectors (PCD), as the core technology of PCCT, differ significantly from traditional Energy Integratin
- 김갑성 기자
- 2025-08-20 10:45
XtalPi Signs MOU with Dong-A ST for Joint Research and Develo…

CAMBRIDGE, Mass., Aug. 20, 2025 -- XtalPi announced on the 20th that it signed a Memorandum of Understanding (MOU) with Korea's leading pharmaceutical company Dong-A ST, to jointly develop therapeutics for immunological and inflammatory diseases. This collaboration will be based on XtalPi's intelligent and automated drug discovery platform, which integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies plan to co-identify targets and discover first-in-class or best-in-class drug candidates using Xta
- 김갑성 기자
- 2025-08-20 08:00
ARC Therapies Advances Gut Microbiome Research with YB32…

[ 메디채널 김갑성 기자 ] Investigating Its Role as an Immune Adjuvant in Cancer Immunotherapy TOKYO, Aug. 20, 2025 -- ARC Therapies Inc. (Head Office: Shinjuku, Tokyo; President & CEO: Rami Suzuki), a certified startup from the National Cancer Center Japan, has initiated research of YB328, a newly identified gut microbe, toward clinical application. Utilizing its proprietary intellectual property, the company has designated the YB328 strain as ARC0812 (RUX: "Lux") and will proceed with preclinical and human clinical trials to evaluate its administration methods and therapeutic e
- 김갑성 기자
- 2025-08-20 07:00
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance…

SHANGHAI, Aug. 19, 2025 -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D code: 7MW4911) received IND clearance from the U.S. Food and Drug Administration (FDA). The clearance enables the initiation of Phase I/II study of 7MW4911 to evaluate the safety, pharmacokinetics, and efficacy in patients with advanced colorectal cancer and other advanced gastrointestinal tumors. 7MW4911 is an investigational CDH17-targeting ADC developed using Mabwell's proprietary IDDC™ platform. Its highly
- 김갑성 기자
- 2025-08-19 22:00
LabConnect Launches LabConnector™ to Streamline Lab…

New service ensures faster, more accurate data delivery to clients JOHNSON CITY, Tenn., Aug. 19, 2025 -- LabConnect, LLC, a global leader in central laboratory services for clinical trials, today announced the launch of LabConnector™, a powerful new technology solution that transforms the way laboratory data is exchanged and managed for clinical trials. LabConnector standardizes diverse laboratory data into a single HL7 format, enabling true bidirectional data transfer across any participating laboratory. LabConnector is purpose-built for IT teams and data analysts at sp
- 김갑성 기자
- 2025-08-19 21:15
WuXi Biologics Reports Solid 2025 Interim Results

[ 메디채널 김갑성 기자 ] Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded by 3.6% YoY to 42.7% EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY Adjusted EBITDA grew 20.6% YoY and adjusted net profit increased 11.6% YoY FY25 group revenue growth target raised to 14% – 16% A first-half record of 86 new integrated projects added, including 2 in late-stage Total integrated projects reached 864, one of the largest portfolios of complex biologics Late-stage and CMO revenue rose 24.9% YoY;
- 김갑성 기자
- 2025-08-19 20:35
Nature Medicine Publishes Results of Phase II Study of Sacit…

CHENGDU, China, Aug. 19, 2025 -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990) announced that clinical data from a Phase II study evaluating novel TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) in combination with PD-L1 monoclonal antibody (mAb) tagitanlimab for the first-line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) have been published in Nature Medicine (Impact Factor: 58.7). The publication highlighted initial findings from the Phase II OptiTROP-Lung01 study, evalua
- 김갑성 기자
- 2025-08-19 20:09

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-08-20_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 20일 21시 00분